Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
TSC Talks! cover art

TSC Talks!

TSC Talks!

Written by: Jill Woodworth
Listen for free

About this listen
TSC TALKS 2.0. Inspired by the condition Tuberous Sclerosis Complex. Providing digital audio & video content and products designed to educate, illuminate, support and advocate "off the grid" alternative and holistic options for marginalized populations. Providing a forum for communication, collaboration, resources and opportunity. Drawing from lived and learned experience All with the goal of coming together to affect change, bridge gaps and empower as we come together to better understand each other's predicament and validate the need for access, affordability that often keep those with chronic, life threatening conditions from exploring options. Options that CAN open the doors of perception to understanding our exceptional variability as human beings and the “one size fits all” aspects of traditional medicine that are not conducive to bio-psycho-social health, stability and longevity. Come join us as we dig deep into issues and concepts that need to be given some thought and discussion in order to truly “walk a mile” in another’s shoes!

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.Copyright Jill Woodworth
Alternative & Complementary Medicine Hygiene & Healthy Living
Episodes
  • TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine
    Nov 20 2026
    SHOW NOTES
    - Dear TSC Alliance Leadership and Natural History Database Steering Committee,.pdf
    - TSC Alliance contact: biosample@tscalliance.org
    - Host contact: Jill Woodworth (pjlacy6@gmail.com)
    - MA AG consumer complaint form: mass.gov/how-to/file-a-consumer-complaint
    - Apertura Gene Therapy press release (May 2026)
    - TSC Alliance NHD page: tscalliance.org
    - Van Andel Institute Biorepository: Grand Rapids, MI
    - Key terms: AAV, TSC1, TSC2, vector sizing, DRG toxicity, antibody neutralization, 15-year FDA follow-up mandate
    ---
    KEY DEFINITIONS
    *AAV Capsid Delivery Platform: An adeno-associated virus (AAV) vector system engineered to deliver functional genetic material into host cells. In this context, it utilizes a viral shell (capsid) to cross specific biological barriers and target neural tissues. Key operational constraints and clinical considerations include:
    *Packaging Limits: AAV vectors have a strict genetic payload capacity of approximately 4.7 kilobases total (including ITRs), leaving roughly 4.4 kilobases for the transgene cassette. Genes exceeding this length (such as full-length TSC2, at ~4.3 kb coding sequence plus necessary promoter and polyA signals) present significant packaging challenges.
    *Immune Response & Irreversibility:** Exposure to an AAV capsid triggers neutralizing antibody production by the patient's immune system, permanently barring subsequent administration of AAV-based treatments.
    *Monitoring Requirements: Regulatory standards (such as FDA mandates) require extended long-term follow-up monitoring—typically lasting up to 15 years—to evaluate long-term safety, potential hepatotoxicity, and dorsal root ganglion (DRG) toxicity.
    I discuss the TSC gene therapy agreement and the TSC Natural History Database (NHD), raising questions about consent, data governance, and long-term impacts on families. I explains the NHD’s scope (running since 2006 with 2,700+ participants, clinical histories and biosamples stored at Van Andel Institute, and thousands of samples distributed to researchers) and critiques the May 2026 TSC Alliance partnership with for-profit Apertura Gene Therapy, backed by Deerfield Management, to develop an AAV gene replacement therapy delivering TSC1/TSC2 to the brain. I outline concerns about lack of reconsent when minors become adults, unclear withdrawal processes, financial protections for participants, and under-communicated risks of AAV therapies (high cost, permanent antibody barrier to future AAV dosing, 15-year monitoring, and TSC2 packaging constraints). I describe a certified letter demanding written answers and offers steps for parents to request consent forms, ask about withdrawal, and file complaints if needed.

    00:00 Intro and Big Questions
    01:57 What We Signed
    02:34 Inside the NHD Database
    03:47 Apertura Partnership Explained
    04:59 Consent and Governance Gaps
    06:30 Gene Therapy Risks Breakdown
    09:29 My Certified Letter
    09:37 Five Demands for Transparency
    12:35 What You Can Do Now
    14:48 Final Thoughts and Wrap Up
    https://aperturagtx.com/news/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc/
    https://www.prnewswire.com/news-releases/apertura-gene-therapy-showcases-the-progress-of-its-novel-human-transferrin-receptor-aav-capsid-tfr1-capx-and-preclinical-programs-for-tuberous-sclerosis-complex-tsc-at-the-american-society-of-gene-and-cell-therapy-asgct-ann-302448607.html
    https://www.prnewswire.com/news-releases/tsc-alliance-and-apertura-gene-therapy-complete-preclinical-pilot-study-evaluating-aav-gene-therapy-approach-designed-for-tsc1-302838523.html

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    16 mins
  • TSC Talks 3.0 (not) Research ~ In the Stone Chamber
    May 6 2026
    Taking a break from the harsh closed loops and hunkering down in dis stone chamber to give a little freestyle riff for this episode from the stone chamber
    no links
    except go watch the video. the audio just won't cut it on this one
    https://youtu.be/bEIqg2lcDU0

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    3 mins
  • TSC Talks 3.0 Research~Episode 10
    Apr 29 2026
    I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.

    Source Links for Further Research
    I. Rare Disease Advocacy and Funding (Conflicts of Interest)
    [TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)
    [TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)
    [TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)
    [TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)
    [NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)
    [NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/)
    [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)
    [Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)
    [NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)
    II. Gene Therapy (CRISPR), Risks, and Regulation
    [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)
    [CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)
    [CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)
    [FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)
    III. Vaccines, Toxins, and Environmental Amplification
    [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)
    [Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/)
    [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)
    [Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)
    IV. Alternative and Holistic Approaches
    [Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-\(mtor\)-pathway)
    [Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)
    [Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)
    [Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)
    contact Jill: pjlacy6@gmail.com

    Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
    Show More Show Less
    36 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet